Olema targets IND for KAT6 drug OP-3136 in Q4 2024; Phase 1/2 starts 2025

Olema Pharmaceuticals, Inc.

Non-clinical data for OP-3136 (KAT6 inhibitor) to be presented at ENA symposium Oct 23-25, 2024.
IND submission for OP-3136 anticipated in Q4 2024.
Phase 1/2 clinical study for OP-3136 expected to begin in 2025.
Potential Phase 3 trial OPERA-02 (palazestrant + ribociclib) initiation planned for 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.